BMO Capital upgrades Alnylam Pharmaceuticals, Inc. PT to $360, citing strong revenue growth

From Yahoo Finance: 2025-06-29 21:50:00

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a top stock in the Growth Stock Portfolio. BMO Capital maintains an ‘Outperform’ rating on ALNY, raising the price target from $300 to $360 due to increased Amvuttra sales and consistent revenue trends. The company develops RNAi therapeutics for rare diseases, showing strong revenue growth.

Despite short-term revenue growth skepticism, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has a history of steady revenue and pipeline growth, indicating potential for further expansion. While ALNY is a solid investment, other AI stocks may offer better returns with less risk. Check out the free report on the best short-term AI stock for more information.

Read more: BMO Capital Maintains ‘Outperform’ Rating on Alnylam Pharmaceuticals, Inc. (ALNY); Raises PT